Lead
The US Food and Drug Administration (FDA) has approved ustekinumab, sold as Stelara, for treating moderately to severely active ulcerative colitis (UC) in paediatric patients, according to reporting from the pharmacy publication Drug Topics. The decision extends an existing adult UC indication and a paediatric Crohn’s disease indication to a younger group of patients whose treatment options have historically been narrower than those available to adults with the same condition.
Background Context
Ulcerative colitis in children is less common than adult-onset disease but can present with more extensive bowel involvement at diagnosis, and it carries particular concerns around growth, nutrition, schooling and quality of life during formative years. Clinicians treating children with UC have often had to rely on medicines licensed primarily in adults, prescribing them off-label when disease does not respond adequately to first-line therapy. Ustekinumab is a monoclonal antibody that works by blocking interleukin-12 and interleukin-23, two signalling proteins involved in the inflammatory processes underlying inflammatory bowel disease (IBD). It already holds approval for moderately to severely active UC and Crohn’s disease in adults, and for paediatric Crohn’s disease, making a paediatric UC indication a logical extension of its established use in IBD.
Key Findings
Drug Topics reported that the FDA’s approval allows ustekinumab to be prescribed on-label for children with moderately to severely active UC, rather than solely through off-label use as had previously been the case. The publication did not detail the specific trial data underpinning the approval within the material reviewed, but noted that the decision follows the same regulatory pathway used for the drug’s earlier paediatric Crohn’s disease approval, in which safety and dosing were assessed in younger patients based on the mechanism and pharmacology already characterised in adults. The approval formally broadens the labelled patient population for a biologic that gastroenterologists already use across the IBD spectrum, giving prescribers a documented, licensed option for children whose colitis has not responded sufficiently to other treatments.
Clinical Relevance
For UK gastroenterologists, IBD nurses and dietitians, this approval is a US regulatory development rather than a change to UK prescribing rules. Ustekinumab is already used in some paediatric UC cases in UK practice, but formal licensing for this population in the United States may inform future discussions with the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) about UK licensing and guidance. Families and clinicians should be aware that any prescribing decisions in the UK continue to depend on current UK licensing status and local specialist advice, not on FDA actions alone.
Reference
The original FDA approval record and any associated manufacturer clinical trial data could not be identified in full from the material reviewed for this article. The information above is drawn from: FDA Approves Stelara for Pediatric Ulcerative Colitis. Drug Topics. Available at: https://www.drugtopics.com/view/fda-approves-stelara-for-pediatric-ulcerative-colitis
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.